Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Recruiting now · Phase 2

Conditions studied: COVID-19

In brief

The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment): A: Small molecule drugs; B: Monoclonal antibodies; C: Dose finding for the constituent parts of nirmatrelvir/ritonavir PLATCOV study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.

Key facts

Study ID

NCT05041907

Run by

University of Oxford

People needed

3800

Starts

2021-09-30

Expected to finish

2027-01-01

Last updated by the study team

2026-02-19

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study.
• Previously healthy adults, male or female, aged 18 to 60 years at time of consent with early symptomatic COVID-19
• SARS-CoV-2 positive by lateral flow antigen test OR a positive PCR test for SARS-CoV-2 within the last 24hrs with a Ct value of less than 25 (all viral targets)
• Symptoms of COVID-19 (including fever, or history of fever) for less than 4 days (96 hours).
• Oxygen saturation ≥96% measured by pulse-oximetry at time of screening.
• Able to walk unaided and unimpeded in ADLs
• Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits

You may not qualify if…

• The patient may not enter the study if ANY of the following apply:
• Taking any concomitant medications or drugs (see appendix 4)†
• Presence of any chronic illness/ condition requiring long term treatment, or other significant comorbidity (e.g. diabetes, obesity but see appendix 4 for the full list)
• Laboratory abnormalities discovered at screening (see appendix 4)
• For females: pregnancy, actively trying to become pregnant, or lactation
• Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics (see appendix 4)
• Currently participating in another COVID-19 therapeutic or vaccine trial
• Evidence of pneumonia (although imaging is NOT required)
• healthy women on the oral contraceptive pill are eligible to join the study

Where it is running

• Laos-Oxford-Mahosot Wellcome Trust Research Unit — Vientiane, Laos (enrolling)
• Faculty of Tropical Medicine, Mahidol University — Bangkok, Thailand (enrolling)
• Sukraraj Tropical & Infectious Disease Hospital — Kathmandu, Nepal (enrolling)
• Universidade Federal de Minas Gerais — Minas Gerais, Brazil (enrolling)
• The Aga Khan University Hospital — Karachi, Pakistan
• Vajira hospital — Bangkok, Thailand
• Bangplee Hospital — Mueang Samut Prakan, Thailand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.